Stockscreener 앱 받기
4.52
7.00%
-0.34
시간 외 거래:
4.52
전일 마감가:
$4.86
열려 있는:
$4.87
하루 거래량:
391.38K
Relative Volume:
2.26
시가총액:
$274.61M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-3.7667
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-5.83%
1개월 성능:
-4.24%
6개월 성능:
-4.44%
1년 성능:
+58.04%
1일 변동 폭
$4.44
$4.97
1주일 범위
$4.44
$4.97
52주 변동 폭
$2.4501
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.52 | 274.61M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Design Therapeutics to Participate in Leerink's Global Healthcare Conference - The Manila Times
Clinical-Stage Biotech Design Therapeutics Gears Up for Key Investor Presentation at Leerink Conference - StockTitan
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies - Yahoo Finance
Can Astria's New HAE Drug Data Transform Treatment? Key Findings Revealed at Major Medical Congress - StockTitan
US Penny Stocks To Watch In February 2025 - Simply Wall St
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA - Morningstar
AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer - Business Wire
Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study - BioSpace
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in January - MarketBeat
AI-based predictive biology coming soon, Foresite’s Bajaj says - BioCentury
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Increased by JPMorgan Chase & Co. - Defense World
Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Yahoo Finance
Harness going after new target, FAN-1, in Huntington’s disease - BioWorld Online
Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Lululemon Athletica Inc. (NASDAQ:LULU) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $900M - Simply Wall St
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Increase in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in December - MarketBeat
Barclays PLC Purchases 24,602 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Jane Street Group LLC - Defense World
Design Therapeutics Updates Corporate Presentation for Investors - TipRanks
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - BioSpace
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases - Yahoo Finance
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
Absci, Owkin announce partnership to bring together AI platforms - Yahoo Finance
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery - Yahoo Finance
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics - Business Wire
Maze Opens 2025 IPO Class to Advance Kidney Disease Programs - BioSpace
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - BioSpace
Barclays PLC Grows Position in Hooker Furnishings Co. (NASDAQ:HOFT) - Defense World
Geode Capital Management LLC Grows Stock Holdings in BARK, Inc. (NYSE:BARK) - Defense World
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Geode Capital Management LLC Buys 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
LPOXY Therapeutics Acquires Assets from Xeno Biosciences - Contract Pharma
Rational design and therapeutic potential of MyD88 inhibitory peptide in psoriasis - ScienceDirect.com
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):